---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015883"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T20:44:12.395994+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# uniQure doses first patient in Phase I/IIa trial of AMT-260 for refractory temporal lobe epilepsy

## Summary
- First patient dosed in GenTLE Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy (MTLE).
- AMT-260 uses AAV9 vector to deliver miRNAs that reduce GluK2 protein subunit expression, targeting seizure triggers.
- Trial includes two dose cohorts of six patients each across 10 U.S. sites; two more sites expected by end of 2024.
- CMO Walid Abi-Saab notes 1/3 of focal seizure patients lack effective treatment, highlighting potential for AMT-260.
- Preclinical studies showed dose-dependent seizure reduction; program updates expected in 2025.

## SEC filing metadata
- accession: 0001558370-24-015883
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000155837024015883/0001558370-24-015883-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000155837024015883/qure-20241121x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015883
- JSON: https://secwatch.observer/filing/0001558370-24-015883.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015883.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.